• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Debra Patt Addresses Medicare’s Successful Reimbursement of Telemedicine

Video

Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, discusses the path of telemedicine reimbursement during the pandemic and possible ways it will change after the pandemic.

Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, discusses the path of telemedicine reimbursement during the pandemic and possible ways it will change after the pandemic, including that some aspects of radiation treatment supervision will go away.

Transcript

How would you characterize telemedicine reimbursement in the oncology setting?

So far, reimbursement is going really well for telemedicine. We know that Medicare has put as part of their proposed fee schedule, the Physician Fee Schedule, reimbursement for telemedicine that will be robust. Only some aspects of radiation treatment supervision will go away after the global pandemic. So when Medicare reimbursement is strong, commercial payers tend to follow and we also were observing that. Now, there are state policies that vary by state regarding telemedicine, so each state has to make sure that they curate and advocate for appropriate telemedicine policy at the state level. But I think telemedicine is here to stay in ways that continue to be clinically meaningful to patient care.

Related Videos
Pat Van Burkleo
Jeff Stark, MD, vice president, head of medical immunology, UCB
Robert Groves, MD
Screenshot of Raajit Rampal, MD, PhD
 Laura Ferris, MD, PhD, professor of dermatology, University of Pittsburgh
Dr Padma Sripada, Columbia Internal Medicine
Screenshot of Jennifer Vaughn, MD, in a Zoom video interview
dr amy paller
Shawn Kwatra, MD, dermatologist, John Hopkins University
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.